Senti Bio reports 2 of 3 AML patients achieve MRD-negative CR in Phase 1 SENTI-202 trial

Senti Biosciences, Inc.

Two of three R/R AML patients at lowest dose (1.0B CAR+ NK cells) achieved CR with MRD negativity; both maintain remission (4+ and 3+ months).
SENTI-202 was generally well-tolerated with no DLTs; adverse events consistent with lymphodepleting chemotherapy and other investigational NK therapies.
Dose escalation continues at 1.5B cells/dose level; additional safety, efficacy and durability data expected in 2025.
SENTI-202 transgene detected in peripheral circulation of all patients across cycles, with PK profile similar to other CAR-NK therapies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.